Studying Immune Cell Function in Men With Prostate Cancer Across Racial Backgrounds
Studies blood samples to compare immune cells in people with prostate cancer.
Key facts
- Who runs it
- Masonic Cancer Center, University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
- Status
- Recruiting
- People taking part
- 45 people, planned
- Started
- 8 Oct 2026
- Expected to end
- 30 Nov 2030
- Type of study
- Observational
- Treatments tested
- Non-Interventional Study
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with prostate cancer, or a likely prostate cancer, who have a planned visit to a University of Minnesota Cancer Clinic. Blood samples will be collected and studied.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Primary prostate cancer (diagnosed, or presumed to be diagnosed)
Main reasons for not taking part
- Cannot or does not want to give written informed consent
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- AIM 1:; Diagnosis (or presumed diagnosis) of primary Prostate cancer; 18 years of age or older; Has a planned visit to a University of Minnesota Cancer Clinic; Willing and able to sign voluntary written consent
Who cannot take part
- AIM 1:; Inability or unwillingness to give written informed consent
Where in United States
- University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Nicholas A. ZorkoTaking people
About the trial
What the trial wants to find out
This study collects, stores and analyzes blood specimens and information from people with prostate cancer. This may help researchers understand whether certain white blood cells involved in immunity differs between prostate cancer patients from various racial backgrounds.
The group in the trial
- Observational
Patients undergo collection of blood samples and have their medical records reviewed on study. Patients may undergo collection of residual tissue samples, if available, on study.
Treatment: Non-Interventional Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
- Plain-language title
- Studying Immune Cell Function in Men With Prostate Cancer Across Racial BackgroundsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 November 2026